PIEJX
Price
$24.25
Change
-$0.44 (-1.78%)
Updated
Sep 6 closing price
RNWFX
Price
$79.55
Change
-$1.12 (-1.39%)
Updated
Sep 6 closing price
Ad is loading...

PIEJX vs RNWFX

Header iconPIEJX vs RNWFX Comparison
Open Charts PIEJX vs RNWFXBanner chart's image
Principal Glb Emerging Markets J
Price$24.25
Change-$0.44 (-1.78%)
VolumeN/A
CapitalizationN/A
American Funds New World R5
Price$79.55
Change-$1.12 (-1.39%)
VolumeN/A
CapitalizationN/A
View a ticker or compare two or three
PIEJX vs RNWFX Comparison Chart
Loading...
VS
PIEJX vs. RNWFX commentary
Sep 07, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PIEJX is a Sell and RNWFX is a Buy.

FUNDAMENTALS
Fundamentals
RNWFX has more cash in the bank: 60.1B vs. PIEJX (518M). PIEJX pays higher dividends than RNWFX: PIEJX (2.02) vs RNWFX (1.51). PIEJX was incepted earlier than RNWFX: PIEJX (24 years) vs RNWFX (22 years). PIEJX (32.40) and RNWFX (32.00) have comparable annual turnover. RNWFX has a lower initial minimum investment than PIEJX: RNWFX (250) vs PIEJX (1000). RNWFX annual gain was more profitable for investors over the last year : 11.53 vs. PIEJX (9.74). RNWFX return over 5 years is better than : 22.38 vs. PIEJX (11.95).
PIEJXRNWFXPIEJX / RNWFX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence24 years22 years-
Gain YTD5.0647.24570%
Front LoadN/AN/A-
Min. Initial Investment1000250400%
Min. Initial Investment IRAN/AN/A-
Net Assets518M60.1B1%
Annual Yield % from dividends2.021.51134%
Returns for 1 year9.7411.5384%
Returns for 3 years-19.92-15.44129%
Returns for 5 years11.9522.3853%
Returns for 10 years6.1135.7117%
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
EGO16.410.29
+1.80%
Eldorado Gold Corp
BIP31.38-0.08
-0.25%
Brookfield Infrastructure Partners LP
KTRA0.17N/A
-2.51%
Kintara Therapeutics
LCTX0.87-0.03
-3.17%
Lineage Cell Therapeutics
NUVB2.88-0.13
-4.32%
Nuvation Bio